Mallinckrodt, the pharmaceuticals business of Covidien, has entered a definitive agreement to acquire CNS Therapeutics, Inc., a privately held specialty pharmaceutical company based in St. Paul, MN, for approximately $100 million. CNS focuses on developing and commercializing products for site-specific administration to the central nervous system to treat neurological disorders and intractable chronic pain. CNS currently has one marketed product and a diverse pipeline of pain and spasticity prod...